Registry of Lobbyists

12-Month Lobbying Activity Search Results

Search Criteria

  1. Corporation, organization or client of the consultant: innovative medicines canada
Share this search Create an alert

Refine By

Activity Status Type Subject matter
Government institution of the DPOH
Government Institutions in Registration Summaries

Search Results for the Last 12 Months

Results: 1-25 of 25
    Active Innovative Medicines Canada / Médicaments novateurs Canada
    In-house Organization: Bettina Hamelin, President
    Monthly Communications: 62
    Active Innovative Medicines Canada
    Consultant: John Delacourt, Counsel Public Affairs
    Monthly Communications: 1
    Active Innovative Medicines Canada
    Consultant: Stephen Sampson, Global Public Affairs
    Monthly Communications: 0
    Active Innovative Medicines Canada / Médicaments novateurs Canada
    Consultant: BRAD LAVIGNE, Counsel Public Affairs Inc.
    Monthly Communications: 0
    Active Innovative Medicines Canada / Médicaments novateurs Canada
    Consultant: Ben Parsons, Counsel Public Affairs Inc.
    Monthly Communications: 0
    Active Innovative Medicines Canada / Médicaments novateurs Canada
    Consultant: William Shelling, Counsel Public Affairs Inc.
    Monthly Communications: 0
    Active Innovative Medicines Canada / Médicaments novateurs Canada
    Consultant: Sheamus Murphy, Counsel Public Affairs Inc.
    Monthly Communications: 0
    Inactive Innovative Medicines Canada
    Consultant: Stuart Barnable, H+K Strategies
    Monthly Communications: 0
    Inactive Innovative Medicines Canada / Médicaments Novateurs Canada
    Consultant: Andrew Balfour, Rubicon Strategy Inc.
    Monthly Communications: 0
    Inactive Innovative Medicines Canada
    Consultant: Will Stewart, Hill+Knowlton Strategies
    Monthly Communications: 0
    Inactive Innovative Medicines Canada
    Consultant: Michelle McLean, Hill+Knowlton Strategies
    Monthly Communications: 0
    Active Innovative Medicines Canada / Médicaments novateurs Canada
    Consultant: Alexander MacDonald, Counsel Public Affairs Inc.
    Monthly Communications: 1
    Active Innovative Medicines Canada / Médicaments novateurs Canada
    Consultant: Chase Tribble, Counsel Public Affairs Inc.
    Monthly Communications: 0
    Inactive Innovative Medicines Canada
    Consultant: Lucas Veiga, Hill+Knowlton Strategies Canada
    Monthly Communications: 1
    Inactive Innovative Medicines Canada / Médicaments novateurs Canada
    Consultant: Elizabeth Campbell, Counsel Public Affairs Inc.
    Monthly Communications: 0
    Inactive Innovative Medicines Canada / Médicaments novateurs Canada
    Consultant: Mike Ras, Counsel Public Affairs Inc.
    Monthly Communications: 0
    Inactive Innovative Medicines Canada
    Consultant: Francis Roy, Hill+Knowlton Strategies Canada / Hill + Knowlton Stratégies
    Monthly Communications: 0
    Inactive Innovative Medicines Canada
    Consultant: Samira Levesque, Hill+Knowlton Strategies Canada / Hill+Knowlton Stratégies
    Monthly Communications: 0
    Inactive Innovative Medicines Canada / Médicaments novateurs Canada
    Consultant: Stephane Berimbere, Hill + Knowlton Strategies
    Monthly Communications: 0
    Inactive Innovative Medicines Canada
    Consultant: Laura Grosman, HILL + KNOWLTON STRATEGIES
    Monthly Communications: 0
    Inactive Innovative Medicines Canada
    Consultant: Eric Dillane, Hill+Knowlton Strategies
    Monthly Communications: 0
    Inactive Innovative Medicines Canada
    Consultant: Andy Singh, Hill and Knowlton Strategies
    Monthly Communications: 0
    Active Eli Lilly Canada Inc.
    Consultant: Beth Palmer, Earnscliffe Strategies
    Monthly Communications: 2
    Active Eli Lilly Canada Inc.
    Consultant: ANDRE ALBINATI, Earnscliffe Strategy Group
    Monthly Communications: 0
    Active Canadian Antimicrobial Innovation Coalition
    Consultant: Danielle Peters, Magnet Strategy Group
    Monthly Communications: 0

Date Modified: